Protego Raises $51M to Support Its Protein-misfolding Therapies

Protego Raises $51M to Support Its Protein-misfolding Therapies

312597

Protego Raises $51M to Support Its Protein-misfolding Therapies

Protego Biopharma has raised $51 million to support the development of therapies for diseases caused by protein misfolding, such as familial amyloid polyneuropathy (FAP). The series A financing was co-led by Lightspeed Venture Partners, Vida Ventures, and MPM Capital. As part of the financing, representatives from these three groups will join the board of directors at Protego. “We are thrilled to partner with a world-class investor syndicate during this pivotal stage as we accelerate the…

You must be logged in to read/download the full post.